As ROS accumulation represents a key pathophysiological process and a driving force in NAFLD and the development of HCC is the ultimate consequence of NAFLD, it is tempting to speculate that enhancing HES5 activity may attenuate NAFLD pathogenesis in vivo. This evidence concerns the gene HES5 and metabolic dysfunction-associated steatotic liver disease.